Tied Tube Trial in Glaucoma Surgery

Sponsor
Washington University School of Medicine (Other)
Overall Status
Recruiting
CT.gov ID
NCT05685485
Collaborator
American Glaucoma Society (Other), University of Pittsburgh (Other)
152
1
27.5
5.5

Study Details

Study Description

Brief Summary

The aim of this study is to assess whether delaying early flow through the Ahmed tube shunt may improve the post-operative surgical outcomes and provide a more predictable outcome. To assess this the investigator will conduct a, randomized prospective, multi-centered study with collaborators at WashU in St. Louis, Duke University, Indiana University and the University of Pittsburgh. Participants will be randomized to have an AGV placement with tube ligation (no-early flow) and without ligation (allowing for early flow). IOP will be measured at day one, week one, and months, one, three six, and twelve. Additionally, clinical data regarding number of glaucoma medications, and complications post-operative complications will also be collected.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Standard Implantation
  • Procedure: Tied off Tube

Detailed Description

The purpose of this study is to compare the post-operative surgical outcomes and complication rates in patients with different surgical techniques in the Ahmed FP7 glaucoma valve implant (New World Medical, Inc., Rancho Cucamonga, CA). In particular, the investigator wishes to assess whether delaying early aqueous flow by using a vicryl ligature (as done in most non-valved glaucoma drainage device implantation) will reduce the hypertensive phase, reduce early encapsulation, and optimize healing dynamics to allow for improved long term IOP results compared to standard implantation techniques.

Aggressive early aqueous flow may introduce inflammatory mediators that may increase fibrosis during wound healing. Furthermore, mechanical compression of the tissue surrounding the plate may further lead to a denser capsule and limit aqueous diffusion through Tenon's and conjunctiva. For these reasons, the investigator postulate's that the limitation of early aqueous flow through the Ahmed valve will reduce the rates of hypertensive phase, lead to a thinner and less encapsulated bleb, reduce complication rates such as hypotony, and lead to overall improvement in long-term IOP reduction.

Study Design

Study Type:
Observational
Anticipated Enrollment :
152 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
The Effects of Temporary Tube Ligation in Ahmed Glaucoma Valve Surgery
Actual Study Start Date :
Oct 18, 2022
Anticipated Primary Completion Date :
Dec 18, 2024
Anticipated Study Completion Date :
Jan 31, 2025

Arms and Interventions

Arm Intervention/Treatment
Standard Implantation

Standard Implantation

Procedure: Standard Implantation
Traditional Ahmed plantation without vicryl ligature

Tied off Tube

Tied off Tube

Procedure: Tied off Tube
Ahmed implantation with vicryl ligature

Outcome Measures

Primary Outcome Measures

  1. IOP Change [Months 1, 3 , 6, and 12]

    Change IOP

Secondary Outcome Measures

  1. Medication Change [Months 1, 3, 6, and 12]

    Change glaucoma medications

Other Outcome Measures

  1. Complication Rate [Months 1, 3, 6, and 12]

    Change Hypotony, Reoperations, Significant Vision Loss

  2. Surgical Case Time [Post op day 0]

    Decrease surgical case time

  3. Capsule Thickness as measured by anterior segment OCT [month 6]

    Capsule Thickness as measured by anterior segment OCT

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Inclusion Criteria:
  • Subjects with age at screening ≥ 18 years

  • Inadequately controlled glaucoma or ocular hypertension

  • Ahmed valve implant as the planned surgical procedure

  • Patients with primary glaucomas (Primary Open Angle Glaucoma or Primary Angle Closure Glaucoma) or pseudoexfoliation, pigmentary and traumatic glaucoma with or without a previous failed trabeculectomy or other intraocular surgery.

  • Primary tubes included

  • Investigators to recruit consecutively all eligible patients from their clinics.

  • Capable and willing to provide consent

Exclusion Criteria:
  • Subjects with NLP vision

  • Subjects unable/unwilling to provide informed consent

  • Unavailable for regular follow up

  • Previous cyclodestructive procedure

  • Prior scleral buckling procedure or other external impediment to drainage device implantation

  • Presence of silicone oil

  • Vitreous in the anterior chamber sufficient to require a vitrectomy

  • Uveitic glaucoma

  • Neovascular glaucoma

  • Nanophthalmos

  • Patients with pathology that may cause elevated episcleral venous pressure

  • Procedure combined with ocular surgery other than cataract surgery (i.e. combined tube-cataract surgery is okay)

  • Any abnormality other than glaucoma in the study eye that could affect tonometry.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Washington University Saint Louis Missouri United States 63108

Sponsors and Collaborators

  • Washington University School of Medicine
  • American Glaucoma Society
  • University of Pittsburgh

Investigators

  • Principal Investigator: James Liu, MD, Washington University St. Louis MO

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Washington University School of Medicine
ClinicalTrials.gov Identifier:
NCT05685485
Other Study ID Numbers:
  • 202206072
First Posted:
Jan 17, 2023
Last Update Posted:
Jan 26, 2023
Last Verified:
Jan 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 26, 2023